Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

The planned funding spans a Phase 3 acne trial, pre-launch work and earlier-stage drug development.

Rhea-AI Summary

Sagimet Biosciences (SGMT) priced an underwritten offering expected to raise approximately $115.0 million in gross proceeds before underwriting deductions and expenses.

The offering includes 8,750,010 Series A common shares at $10.00 each and pre-funded warrants to purchase 2,750,010 shares at $9.9999 per warrant. Closing is expected on or about October 1, 2026, subject to customary closing conditions. Commodore Capital is leading the financing. Sagimet intends to use net proceeds and existing funds for a Phase 3 denifanstat acne trial, denifanstat pre-launch activities, TVB-3567 through Phase 2 topline results, and its topical FASN inhibitor program through submission of an investigational new drug application, alongside general corporate purposes.

5 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Offering proceeds are expected to total approximately $115.0 million gross, before underwriting deductions and expenses. 20% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to fund a Phase 3 denifanstat trial in acne using proceeds and existing funds.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to fund denifanstat pre-launch activities using proceeds and existing funds.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to fund TVB-3567 through Phase 2 topline results using proceeds and existing funds.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to advance its topical FASN inhibitor program to investigational new drug application submission.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.8,750,010 new Series A common shares at $10.00 each dilute existing shareholders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants for 2,750,010 shares cost $9.9999 each, with a $0.0001-per-share exercise price, adding dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting discounts, commissions and other offering expenses will reduce net proceeds.

News Explained

The warrant terms mean existing holders’ ownership percentage can fall if those warrants are exercised.

Sagimet has priced an issuer-sale of shares and pre-funded warrants, with closing expected around October 1, 2026, subject to customary conditions; if completed, the company receives expected gross proceeds and issues shares, with warrants adding potential shares upon exercise.

The warrants are immediately exercisable at $0.0001 per share after purchase for $9.9999 each; on exercise they convert into shares, increasing the share count and reducing existing holders’ percentage ownership absent offsets.

At the second-quarter operating-cash-outflow rate, $115.0 million of gross proceeds equals 942.9 days of historical outflow, while cash and investments reported at June 30, 2026 equal 2,111.8 days at that same rate.

Sources and calculations

• Sagimet Biosciences offering-pricing release (2026-09-30)
• Pre-funded warrant definition (undated)
• Dilution definition (undated)
• Sagimet second-quarter 2026 financial metrics (2026Q2)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $115,000,000 / ($11,099,000 / 91) = 942.9 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($165,896,000 + $74,232,000 + $17,436,000) / ($11,099,000 / 91) = 2111.8 days

Argus 15 min delay 9 alerts

+3.97% vs previous close $9.70 last price 0.1x rel. volume Open Argus

Details

Market move: SGMT +3.97% vs previous close. Series A public offering

+8.9% Peak in 0 min

$9.09 – $11.00 Day Range

$602.94M Market Cap

On Sep 30, the day this news came out, the latest delayed price for SGMT is 3.97% above the previous close. Argus tracked a peak move of +8.9% during the session. Our momentum scanner has recorded 9 alerts for this stock so far that day. The latest delayed price is $9.70.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Series A shares: 8,750,010 shares at $10.00 per share Pre-funded warrants: 2,750,010 warrants at $9.9999 per warrant Warrant exercise price: $0.0001 per share +2 more

Series A shares

8,750,010 shares at $10.00 per share

Underwritten offering

Pre-funded warrants

2,750,010 warrants at $9.9999 per warrant

Offered in lieu of Series A common stock for certain investors

Warrant exercise price

$0.0001 per share

Warrants exercisable immediately

Expected gross proceeds

Approximately $115.0 million

Before underwriting discounts, commissions and other offering expenses

Expected closing

On or about October 1, 2026

Subject to customary closing conditions

Previous Offering Reports

1 past event · Latest: Apr 27

Same Type 1 event

1. Apr 27

   underwritten offering

   24h Move

   +38.6%

   Raised $175 million for denifanstat Phase 3 and other pipeline programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten offering, pre-funded warrants, shelf registration statement

3 terms

underwritten offering financial

"pricing of an underwritten offering of 8,750,010 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

pre-funded warrants financial

"pre-funded warrants to purchase 2,750,010 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by Sagimet. The offering is expected to close on or about October 1, 2026, subject to the satisfaction of customary closing conditions.

The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including RA Capital Management, Spruce Street Capital, BVF Partners L.P., Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors, LLC, and Woodline Partners LP.

Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Canaccord Genuity, H.C. Wainwright & Co., Jones and Clear Street are acting as co-lead managers for the offering.

Sagimet intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, pre-launch activities for denifanstat, TVB-3567 through Phase 2 topline results, advancement of its topical formulation FASN inhibitor program to IND submission and for general corporate purposes, including additional clinical development, working capital and operating expenses.

A shelf registration statement on Form S-3 (File No. 333-281582) relating to these securities was filed with the Securities and Exchange Commission (the “SEC”) and declared effective on August 26, 2024. A prospectus supplement relating to the offering, and the accompanying prospectus, will be filed with the SEC. When available, copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, without limitation, statements regarding the satisfaction of customary closing conditions relating to the offering and sale of securities, Sagimet’s ability to complete the offering, the anticipated gross proceeds from the offering and the intended use of the proceeds from the offering. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to market conditions and satisfaction of customary closing conditions related to the offering and other risks and uncertainties described under the heading “Risk Factors” in documents Sagimet files from time to time with the SEC. There can be no assurance as to whether the offering may be completed. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause Sagimet’s actual results to differ may emerge from time to time, and it is not possible for Sagimet to predict all of them. Sagimet undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Sagimet Biosciences raising, and what are the offering prices?

Sagimet expects approximately $115.0 million in gross proceeds, before underwriting discounts, commissions and other offering expenses. The offering prices are $10.00 per Series A common share and $9.9999 per pre-funded warrant.

When is Sagimet Biosciences expected to close the offering?

The offering is expected to close on or about October 1, 2026, subject to the satisfaction of customary closing conditions.

When can Sagimet Biosciences offering pre-funded warrants be exercised?

The pre-funded warrants are exercisable immediately, with an exercise price of $0.0001 per share.